Cancer
| 2 min read
PerkinElmer has expanded and deepened its screening and diagnostics offerings with the acquisition of Spectral Genomics’ assets for molecular karyotyping technology used to evaluate chromosomal abnormalities.
| 3 min read
Former Neos Discovery has taken on a new name to more accurately reflect its area of expertise—Trana Discovery—and has also brought on board five former Glaxo executives to commercialize the company’s technology.
| 2 min read
In a move that will expand its oncology pipeline, Biogen Idec announced the signing of a definitive merger agreement for the acquisition of Conforma Therapeutics Corp.
| 2 min read
Bay Area protein therapeutics and discovery company FivePrime Therapeutics Inc. inks a two-year research and license deal with Boehringer Ingelheim.
| 2 min read
In a recent issue of Science, researchers believe they have found a way to selectively target G protein-coupled receptors (GPCRs) with small-molecule compounds that interrupt protein-protein interactions.
| 3 min read
Merck spends $480 million to acquire GlycoFi and Abmaxis to further strengthen its antibody and yeast expression technologies
| 1 min read
At the Strategic Research Institute’s Targeting Ubiquitin for Drug Discovery & Development conference
| 1 min read
At the recent meeting of the American Society of Clinical Oncology
| 3 min read
In a deal worth potentially just over a half billion dollars, SGX Pharmaceuticals is embarking on a license and collaboration agreement with Novartis that focuses on the development and commercialization of BCR-ABL inhibitors for the treatment of drug resistant chronic myelogenous leukemia (CML).
